Modified tuberculosis vaccine as therapy against bladder cancer

March 5, 2020

The Max Planck Insitute for Infection Biology is sharing news of interest to the Immunology Community.

Therapy with VPM1002 is effective in bladder cancer patients

The human immune system can recognize and eliminate not only germs but also cancer cells. This is why treatments with weakened germs can help the immune system it ist fight against cancer.

The Max Planck Insitute for Infection Biology has developed a vaccine against TB which is currently in phase III trial. Less known is that this vaccine is also tested for treatment of bladder cancer and it has now shown a remarkable outcome in a clinical trial in preventing cancer recurrence.

clinical trial no.: NCT02371447 (https://clinicaltrials.gov/ct2/show/NCT02371447)

More News

2021 Edition: Day of Immunology

June 17, 2021

2021 International Day of Immunology

June 7, 2021

Chinese Society for Immunology (CSI) Training Courses in 2020

March 4, 2021

Michelson Prizes

March 4, 2021

FUNDING OPPORTUNITY FROM IUIS AND FOCIS FOR IMMUNOLOGISTS FROM THE DEVELOPING WORLD – For Participation in Virtual Advanced Course in Basic & Clinical Immunology on March 1-3, 2021, USA

February 17, 2021

New Webinar Series: Immunology without Borders

February 2, 2021

IUIS/AAI AWARDS: SUMMER COURSES in IMMUNOLOGY

January 18, 2021

News from ICLAS

December 17, 2020

GEC Statement on the Publication “The association between early career informal mentorship in academic collaborations and junior author performance”

December 16, 2020